From €74.00 €62.90
Mdivi 1 is a mitochondrial division inhibitor.{25445,62513} It inhibits the GTPase activity of yeast, but not human, dynamin-1 (Dnm1; IC50 = ~1-10 µM for the recombinant yeast enzyme) and human dynamin-related protein 1 (DRP1) in A549 lung cancer cells when used at a concentration of 50 µM. Mdivi 1 (50 µM) inhibits mitochondrial fragmentation and DRP1 self-assembly induced by staurosporine (Item No. 81590) in COS cells overexpressing DRP1.{25445} It induces apoptosis in, and inhibits colony formation of, A549 cells when used at concentrations of 25 and 50 µM, respectively.{62513} Mdivi 1 (1 µM) decreases doxorubicin-induced increases in infarct-to-risk ratios in a Langendorff isolated perfused rat heart model of ischemia-reperfusion injury.{25446} It reduces the severity of lung injury in a mouse model of LPS-induced acute lung injury when administered at a dose of 20 mg/kg.{62514}
Territorial Availability: Available through Bertin Technologies only in France
| Size | 10 mg, 25 mg, 5 mg, 50 mg |
|---|---|
| Shipping | dry ice |
| CAS number | 338967-87-6 |
| Molecular formula | C15H10Cl2N2O2S |
| Smiles | SC(N1C2=C(Cl)C=C(Cl)C(OC)=C2)=NC3=CC=CC=C3C1=O |
| Molecular weight | 353,2 |
| Custom code | 2933.49 |
| Formulation | A crystalline solid |
| Purity | ≥98% |
| UNSPSC code | 12352100 |
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.
GST-tag Polyclonal Antibody (FITC) is a probe for the immunochemical detection of GST tags on recombinant proteins. Recombinant proteins are...
Programmed cell death protein 4 (PDCD4) levels are elevated during apoptosis and absent in many cancer samples.{16340,16167} Loss of PDCD4...
This mixture contains the characteristic metabolites of both PGI2 and TXA2. Contents: Thromboxane B2, 11-dehydro Thromboxane B2, 6-keto Prostaglandin F1?,...
Headquarters:
Parc d’activités du Pas du Lac
10 bis avenue Ampère
78180 Montigny le Bretonneux
France
Copyright © 2024 BERTIN BIOREAGENT. All rights reserved | Terms & conditions
